Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma

NCT04458922 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04458922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04458922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 5, 2020
Completion date
December 17, 2026
Enrollment
27 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

central chondrosarcoma, grade 2, central chondrosarcoma, grade 3, dedifferentiated chondrosarcoma, metastatic clear cell sarcoma of soft tissue, metastatic primary central chondrosarcoma, unresectable primary central chondrosarcoma